OBSOLETE: Vascular disruption sequence

Vascular disruption sequence (also known as vascular disruption defects or vascular disruption anomalies) is an obsolete clinical designation that was previously used to describe a heterogeneous group of congenital anomalies thought to arise from interruption of normal blood supply during embryonic or fetal development. The concept encompasses a range of structural birth defects — including limb reduction defects, intestinal atresias, gastroschisis, porencephaly, and other tissue loss or malformation patterns — attributed to vascular compromise such as thrombosis, embolism, or mechanical disruption of blood vessels in utero. Body systems potentially affected include the musculoskeletal system (limb deficiencies, terminal transverse defects), the central nervous system (hydranencephaly, porencephaly), the gastrointestinal tract (intestinal atresia), and the abdominal wall (gastroschisis). Because the underlying mechanism is a disruptive event rather than a primary genetic malformation, the resulting defects are typically asymmetric and non-hereditary. This Orphanet entry (ORPHA:3160) is now classified as obsolete, meaning the concept has been retired or redistributed into more specific diagnostic entities within current nosology. The individual conditions previously grouped under this umbrella term are now classified and managed separately. Treatment depends entirely on the specific anomaly present and may include surgical correction (e.g., for intestinal atresia or limb anomalies), supportive care, rehabilitation, and prosthetic devices. There is no single unifying therapy, as management is tailored to the particular organ system involved and the severity of the defect. Genetic counseling may be offered to families, though recurrence risk is generally considered low given the sporadic, non-genetic nature of most vascular disruption events.

Inheritance

Sporadic

Usually appears on its own, not inherited from a parent

Age of Onset

Neonatal

Begins at or shortly after birth (first 4 weeks)

Source: openFDA + DailyMed · NDA / BLA labels with structured indications · refreshed weekly

Source: ClinicalTrials.gov · synced daily · phases, status, and PI names normalized at ingest

Source: NPI Registry + PubMed · trial PI roles cross-referenced with ClinicalTrials.gov · ranked by match score (publications + PI activity + community signal)

Source: NORD Rare Disease Centers + NIH Undiagnosed Diseases Network (UDN) · centers verified active within last 12 months

Source: PubMed + NIH RePORTER + openFDA + clinical-journal RSS · last 30 days · disease-tagged at ingest by AI extraction with human QC

Common questions about OBSOLETE: Vascular disruption sequence